Board appointments following recent $95 million CAD Series C Financing Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse
Series C financing led by NEA Provides advancement of INV-202 Phase 2 clinical trial in Diabetic Kidney Disease in Q4 Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique
Inversago Pharma Inc : Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European